Document is current
Any future updates will be listed below
-
Authors
Liberale, Luca
Tual-Chalot, Simon
Sedej, Simon
Ministrini, Stefano
Georgiopoulos, Georgios
Grunewald, Myriam
Bäck, Magnus
Bochaton-Piallat, Marie-Luce
Boon, Reinier A.
Ramos, Gustavo Campos
de Winther, Menno P. J.
Drosatos, Konstantinos
Evans, Paul C.
Ferguson, Jane F.
Forslund-Startceva, Sofia K.
Goettsch, Claudia
Giacca, Mauro
Haendeler, Judith
Kallikourdis, Marinos
Ketelhuth, Daniel F. J.
Koenen, Rory R.
Lacolley, Patrick
Lutgens, Esther
Maffia, Pasquale
Miwa, Satomi
Monaco, Claudia
Montecucco, Fabrizio
Norata, Giuseppe Danilo
Osto, Elena
Richardson, Gavin D.
Riksen, Niels P.
Soehnlein, Oliver
Spyridopoulos, Ioakim
Van Linthout, Sophie
Vilahur, Gemma
Wentzel, Jolanda J.
Andrés, Vicente
Badimon, Lina
Benetos, Athanase
Binder, Christoph J.
Brandes, Ralf P.
Crea, Filippo
Furman, David
Gorbunova, Vera
Guzik, Tomasz J.
Hill, Joseph A.
Lüscher, Thomas F.
Mittelbrunn, María
Nencioni, Alessio
Netea, Mihai G.
Passos, João F.
Stamatelopoulos, Kimon S.
Tavernarakis, Nektarios
Ungvari, Zoltan
Wu, Joseph C.
Kirkland, James L.
Camici, Giovanni G.
Dimmeler, Stefanie
Kroemer, Guido
Abdellatif, Mahmoud
Stellos, Konstantinos
- License Information
-
More Information
Article History
Accepted: 22 January 2025
First Online: 19 February 2025
Competing interests
: L.L. is co-inventor on international patent WO/2020/226993 filed in April 2020, relating to the use of antibodies that specifically bind to IL-1α to reduce the sequelae of ischaemia–reperfusion injury to the central nervous system, and has received financial support from the Swiss Heart Foundation and the Novartis Foundation for Medical–Biological Research outside the topic of this Review. M. Giacca is a scientific founder, consultant, member of the board and equity holder in Forcefield Therapeutics, Heqet Therapeutics and Purespring Therapeutics. M.K. is listed as inventor in patents related to the manipulation of adaptive immunity for the prevention or treatment of cardiovascular disease. P.M. reports consulting fees from Pangea Botanica and Orion Biotechnology. G.D.N. declares research grants from Novartis, consultancy fees from Amarin, Amgen, Meda Pharma and MSD, and speaker bureau fee from MSD. O.S. receives funding from Novo Nordisk and serves as consultant to Roche and Novo Nordisk. L.B. acts as scientific adviser of the Berlin Institute of Health, Sanofi, Ionnis, Pfizer and Novo Nordisk; receives educational grants from Sanofi and Bayer; and founded the Spin-off Ivastatin Therapeutics SL (all unrelated to this work). V.G. is scientific advisory board member for GenFlow, MatrixBio, DoNotAge and BellSant. T.F.L. reports educational and research funding from Abbot, Amgen, AstraZeneca, Boehringer Ingelheim, Daichi-Sankyo, Eli Lilly, Novartis, Novo Nordisk, Sanofi and Vifor. M.G.N. is the scientific founder of Biotrip, Lemba and TTxD. J.C.W. is the scientific founder of Greenstone Biosciences. J.L.K. has a financial interest related to this area including patents and pending patents covering senolytic drugs and their uses, which are held by the Mayo Clinic; this Review article has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic conflict of interest policies. G.G.C. is coinventor on international patent WO/2020/226993 filed in April 2020, which relates to the use of antibodies that specifically bind to IL-1α to reduce sequelae of ischaemia–reperfusion injury to the central nervous system. G.K. has held research contracts with Daiichi-Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro, Tollys and Vascage; is on the Board of Directors of the Bristol Myers Squibb Foundation France; is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio; is on the scientific advisory boards of Hevolution, Institut Servier, Longevity Vision Funds and Rejuveron Life Sciences; and is the inventor of patents covering therapeutic targeting of ageing, cancer, cystic fibrosis and metabolic disorders; G.K.’s wife, L. Zitvogel, has held research contracts with GSK, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi-Sankyo, Pilege, Merus, Transgene, 9m, Tusk and Roche, was on the Board of Directors of Transgene, is a co-founder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota; G.K.’s brother, R. Kroemer, was an employee of Sanofi and now consults for Boehringer Ingelheim. M.A. is involved in patents dealing with the cardiometabolic benefits of spermidine, nicotinamide and acyl coenzyme A binding protein. The other authors declare no competing interests.
